680 articles in this topic
A phase trial finds paricalcitol safely remodels the tumor microenvironment in metastatic pancreatic cancer, boosting immune cell infiltration.
Removing dietary copper starves leukemia cells of nucleotide building blocks, boosting methotrexate efficacy against hard-to-treat CNS disease.
McGill scientists boosted NK cell cancer-killing power using reversible drug treatment, targeting leukemia, glioblastoma, and triple-negative breast cancer.
A landmark study of 500 cat tumors reveals shared cancer-driving mutations with humans, pointing toward new breast cancer treatments.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
A phase II trial tests whether sunitinib retains activity in metastatic renal cell carcinoma after first-line immunotherapy resistance.
Sevabertinib and zongertinib win FDA approval for HER2-mutant NSCLC, expanding targeted therapy options for previously treated patients.
A Lancet Healthy Longevity editorial calls for systemic elevation of cancer survivorship care as a public health and longevity priority.
A newly discovered molecular pathway explains why many colorectal cancers resist immunotherapy — and points to a druggable target.
A landmark Cell study reveals cells transfer cytoplasmic DNA fragments to neighbors via nanotubes, stably reshaping recipient genomes.
Scientists engineered a fusion protein that recruits abundant immune cells to cross-present tumor antigens, boosting anticancer immunity in mice.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
